Europe's headline clinical trial target is not a regulatory metric. It runs from application submission to first participant recruited, and most of that window sits with the sponsor.
ACT EU, the Accelerating Clinical Trials in the EU initiative, was launched in January 2022 by the European Commission, the European Medicines Agency and the Heads of Medicines Agencies. It builds on the Clinical Trials Regulation and on the Clinical Trials Information System, which went live on 31 January 2022.
The initiative now publishes progress against two headline targets, with data covering activity to the end of June 2026.
The first is volume: 84 multinational clinical trials authorised in addition to the historical average, against a goal of 500 extra multinational trials by the end of 2030.
The second is speed, and it is the one worth dwelling on. 40.8 percent of trials recruit participants within 200 days from application submission, against a goal of 66 percent by the end of 2030.
Read that definition again. The clock starts at application submission and stops when the trial recruits participants. It does not stop at authorisation.
A metric that ended at authorisation would be a regulatory performance measure. Sponsors could report against it, argue about it, and reasonably say the outcome was determined by assessment timelines outside their control.
A metric that ends at first participant recruited is something else. It spans regulatory assessment, national implementation, ethics approval, site contracting, site activation, supply release, system setup and the first successful screening visit. Only the first portion belongs to regulators.
That makes it an honest measure of the whole system rather than of one participant in it, and it also means a sponsor cannot improve its position on this metric by waiting for authorisation timelines to shorten. A faster assessment that hands the trial to an organisation not ready to activate simply moves the delay later in the window.
Which is the useful reframing. The 200-day target is a question about operational readiness at least as much as about regulatory throughput.
The post-authorisation portion of that window is well understood and rarely measured with any precision.
Contract execution is usually the largest single block, and the most variable. Negotiation cycles differ by country, by institution type and by how far the sponsor's template departs from local norms. Ethics implementation and national requirements follow, with country-specific documents that are frequently rebuilt per study rather than maintained as versioned assets.
Then comes site activation: staff provisioning across systems, training completion, delegation logs, equipment and supply release, and the checks that must be satisfied before a site is green-lit to screen. Each of these has a dependency chain, and in most organisations those chains are managed sequentially because that is how the checklist was written, not because the risk requires it.
None of this is exotic. It is ordinary operational work, distributed across several functions and usually several systems, with no single view of where a given country actually stands.
Here is the practical difficulty. Most organisations cannot currently report their own performance against the 200-day definition without assembling it by hand.
Submission dates sit in regulatory tracking. Authorisation dates come back through CTIS. Contract status sits with legal or outsourcing. Site activation dates sit in the CTMS. First screening and first enrollment sit in EDC. Producing a single elapsed figure per country means joining five sources on identifiers that were never designed to match.
So the number gets produced quarterly, retrospectively, for a governance deck. By the time it is visible, every study it describes has already finished the window it was measuring.
A metric that can only be calculated after the fact cannot be managed. It can only be reported.
This is where a unified eClinical platform changes what is possible, and the change is less about capability than about adjacency.
Cloudbyz holds Study Start-Up, eRegulatory, CTMS, Budgets and EDC on one platform, which means submission date, authorisation date, contract stage, activation readiness and first enrollment are attributes of the same country and site records. The elapsed time from submission to first participant is a field rather than a reconciliation exercise.
Two things follow from that, and they matter more than the dashboard itself.
Parallel paths become manageable. Much of the sequencing in study start-up is convention rather than requirement. Running contracting alongside regulatory review, and site preparation alongside contracting, is only safe when dependencies are explicit and status is current. With both in one system, parallel becomes the default and sequential needs a reason.
Country documentation stops being rebuilt. A versioned, country-specific document library in eRegulatory turns submission package assembly into a review rather than a drafting exercise, which removes a category of rework that never appears in any metric but consumes real weeks.
ACT EU's progress is reviewed annually by its governance on the basis of quarterly reports, and the targets run to 2030. That is a long enough horizon that the system will very likely move toward them.
But a sponsor's position on the 200-day metric is not determined by that movement alone. It is determined by how much of the post-authorisation window that sponsor can compress, and that portion is available to work on now, without waiting for anything.
The first step is being able to see the clock while it is still running.